论文部分内容阅读
目的探讨小儿咳嗽变异性哮喘应用布地奈德联合孟鲁司特治疗的临床疗效及肺功能的变化。方法选择2011年8月至2013年12月收治的咳嗽变异性哮喘儿童92例作为研究对象,根据用药的不同随机分为布地奈德组与联合组各46例,布地奈德组在常规治疗的基础上加用布地奈德气雾剂,联合组在布地奈德组治疗的基础上加用孟鲁司特进行治疗,对两组的疗效及肺功能的变化情况进行对比分析。结果联合组治疗总有效率为95.65%,显著优于对照组的76.09%。比较差异有统计学意义(P<0.05);治疗8周后两组的肺功能指标均较治疗前有显著改善(P<0.05),但联合组的改善更为显著,差异有统计学意义(P<0.05)。结论布地奈德联合孟鲁司特治疗小儿咳嗽变异性哮喘临床效果明显,且能显著改善患儿的肺通气功能,值得在临床应用中推广。
Objective To investigate the clinical efficacy and changes of lung function in children with cough variant asthma treated with budesonide and montelukast. Methods Ninety-two children with cough variant asthma admitted from August 2011 to December 2013 were selected as study subjects, and randomly divided into budesonide group and combination group of 46 patients according to the different medication. Budesonide group was given routine treatment Based on the use of budesonide aerosol, the combination group on the basis of the treatment of budesonide plus montelukast for treatment, the efficacy of the two groups and lung function changes were compared. Results The total effective rate of the combination group was 95.65%, which was significantly better than 76.09% of the control group. (P <0.05). After 8 weeks of treatment, the pulmonary function indexes of both groups were significantly improved (P <0.05), but the improvement in the combination group was more significant (the difference was statistically significant (P < P <0.05). Conclusion Budesonide montelukast treatment of children with cough variant asthma clinical effect is obvious, and can significantly improve children’s pulmonary ventilation, it is worth promoting in clinical application.